Enoxaparin

Introduction Overview

Generic Name

Enoxaparin

Brand Name

Lovenox

Dosage Form

Injection (subcutaneous and intravenous)

Drug Class

Heparins

Pharmacokinetics

Absorption:
Enoxaparin is administered parenterally, mostly via subcutaneous injection, as it is not absorbed orally. After subcutaneous administration, enoxaparin is rapidly absorbed, reaching peak anti-factor Xa activity in approximately 3 to 5 hours. The bioavailability following subcutaneous administration is approximately 90%. The absorption is consistent and predictable, allowing for dosing without the need for routine monitoring in most patients. Absorption may be affected by injection site and patient factors such as obesity or edema.

Distribution:
Once absorbed, enoxaparin predominantly remains in the vascular compartment due to its high affinity for antithrombin III and interactions with endothelial surfaces. It exhibits a relatively small volume of distribution approximating plasma volume (about 4 to 5 liters), indicating limited tissue penetration. Enoxaparin does not significantly cross the placenta nor the blood-brain barrier. The protein binding of enoxaparin is high, specifically binding antithrombin and other plasma proteins. The binding to plasma proteins can be saturable, potentially affecting pharmacodynamics at higher doses.

Metabolism:
Enoxaparin undergoes partial hepatic metabolism primarily by desulfation and depolymerization. This metabolism results in inactivation of the molecule, producing smaller low-molecular-weight fragments that exhibit diminished anticoagulant activity. The metabolic pathways are not fully elucidated but involve enzymes such as heparinases and sulfatases. Because enoxaparin is metabolized in the liver, hepatic impairment can alter drug levels and anticoagulant response.

Elimination:
The primary route of elimination for enoxaparin and its metabolites is renal excretion. Approximately 40% of administered enoxaparin is excreted unchanged in the urine. The elimination half-life is dose-dependent and ranges from 4.5 hours after a single 1 mg/kg subcutaneous dose to approximately 7 hours with multiple dosing. Patients with renal impairment have decreased clearance and prolonged half-life, and dose adjustment is necessary to mitigate bleeding risk. Enoxaparin is not significantly eliminated by bile or feces. Hemodialysis removes only a small fraction of the drug due to its high molecular weight and protein binding.

Dosage Forms

Available Dosage Forms:
Lovenox is available in several formulations for subcutaneous injection including:
- Prefilled syringes (single-use) with fixed doses:
• 30 mg/0.3 mL
• 40 mg/0.4 mL
• 60 mg/0.6 mL
• 80 mg/0.8 mL
• 100 mg/1 mL
• 120 mg/0.8 mL
• 150 mg/mL
- Multi-dose vials containing benzyl alcohol preservative:
• 300 mg/3 mL
• 400 mg/4 mL
Standard packaging is designed for convenience and accuracy during administration, including dosage increments rounded to the nearest 10 mg for ease of use in clinical settings.

Dosages for Adults and Adolescents:
Dosage varies based on indication, renal function, and patient weight. Typical dosing regimens include:
- Prophylaxis of deep vein thrombosis (DVT): 30 mg every 12 hours or 40 mg once daily subcutaneously.
- Treatment of acute DVT without pulmonary embolism: 1 mg/kg subcutaneously every 12 hours or 1.5 mg/kg once daily.
- Treatment of acute ST segment elevation myocardial infarction (STEMI): 30 mg IV bolus plus 1 mg/kg subcutaneously, then 1 mg/kg subcutaneously every 12 hours.
- Dosage adjustments are required in patients with renal impairment (creatinine clearance <30 mL/min), generally a reduction to 1 mg/kg once daily.

Specific Patient Populations:
- Renal Impairment: Dose adjustments to reduce bleeding risk are critical; often dosing to once daily is advised.
- Obesity: Weight-based dosing is recommended; care should be taken for dosing accuracy.
- Pregnancy: Enoxaparin is preferred over warfarin during pregnancy due to lack of teratogenicity; preservative-free formulations are commonly used.
- Elderly: No specific dose adjustment solely based on age, but increased bleeding risk necessitates careful monitoring.
- Pediatric use: Limited data exist; dosing unfamiliar and requires specialist consultation.

Administration Sites:
- Preferred injection sites include the abdomen (excluding a 2-inch circumference around the navel), upper outer thigh, upper buttocks, or outer upper arm, all areas rich in subcutaneous fatty tissue to enable optimal absorption and reduce local irritation.

Mechanism Of Action

Enoxaparin is a low molecular weight heparin (LMWH) that exerts its anticoagulant effects primarily through potentiation of antithrombin III activity. By binding to antithrombin III, enoxaparin accelerates its inhibition of activated factor Xa, a critical enzyme in the coagulation cascade responsible for conversion of prothrombin to thrombin. This inhibition leads to a reduction in thrombin generation and subsequent fibrin clot formation.

Unlike unfractionated heparin, enoxaparin has a higher ratio of anti-factor Xa to anti-factor IIa (thrombin) activity, typically around 4:1, which results in more targeted anticoagulation with less effect on thrombin. This selective inhibition decreases thrombin formation without significantly affecting other coagulation factors, leading to predictable anticoagulant effects, reduced side effects, and less frequent monitoring requirements.

At the cellular level, enoxaparin interrupts the amplification of the coagulation cascade, thus preventing the extension and formation of pathological thrombi in the venous and arterial systems. It also exhibits minor anti-inflammatory effects that may contribute to its utility in acute coronary syndrome by inhibiting leukocyte adhesion and decreasing vascular inflammation.

Clinical trials and biochemical studies have demonstrated that enoxaparin's mechanism leads to effective prevention and treatment of venous thromboembolism and reduces thrombotic complications in acute coronary syndromes. Compared to unfractionated heparin, enoxaparin offers more predictable pharmacokinetics, allowing fixed dosing and outpatient use. Research supports its superior safety profile, especially with respect to lower risks of heparin-induced thrombocytopenia.

Pharmacological Actions

Potentiation of antithrombin III leading to selective inhibition of factor Xa
Inhibition of thrombin formation with lower anti-IIa activity compared to unfractionated heparin
Prevention of fibrin clot formation and propagation
Reduction in venous thromboembolism (VTE) formation and propagation
Prevention of deep vein thrombosis and pulmonary embolism
Reduction of ischemic complications in acute coronary syndromes
Minimal binding to plasma proteins resulting in predictable anticoagulant responses
Low risk of heparin-induced thrombocytopenia compared to unfractionated heparin
Limited interference with platelet function
Anti-inflammatory effects contributing to vascular protection
Facilitation of outpatient anticoagulant therapy due to predictable pharmacokinetics
Inhibition of early stages of coagulation cascade amplification
Reduced impact on activated partial thromboplastin time (aPTT) allowing fixed dosing

Therapeutic Or Clinical Uses

Prophylaxis of deep vein thrombosis (DVT) in patients undergoing abdominal surgery, hip or knee replacement surgery
Treatment of acute deep vein thrombosis with or without pulmonary embolism
Prevention of venous thromboembolism in medically ill patients at risk
Management of acute coronary syndromes including unstable angina and non-ST elevation myocardial infarction
Adjunct treatment in ST segment elevation myocardial infarction (STEMI) with thrombolytic therapy
Prevention of blood vessel complications in patients with angina
Use during pregnancy for prophylaxis or treatment of thromboembolic disorders when oral anticoagulants are contraindicated
Treatment or prevention of clot formation in patients immobilized due to prolonged illness or surgery
Bridge therapy for patients requiring temporary anticoagulation interruption
Prophylaxis of clot formation in patients with central venous catheters or hemodialysis
Off-label use as anticoagulant in low-risk thrombosis conditions under specialist guidance
Treatment of thrombosis associated with malignancy in combination with other therapies
Preventing clot extension and recurrent thrombosis
Use in hospitalized patients with multiple risk factors for thrombosis

Side Or Adverse Effects

Injection site reactions including pain, bruising, redness, and irritation
Bleeding complications ranging from minor bruising to serious hemorrhage
Heparin-induced thrombocytopenia (HIT) though less frequent than with unfractionated heparin
Anemia due to blood loss or bleeding
Nausea and diarrhea
Confusion and headache in some patients
Allergic reactions including hives, itching, burning skin, and anaphylaxis
Spinal or epidural hematoma particularly when combined with spinal procedures or certain drugs
Elevated liver enzymes in rare cases
Osteoporosis with prolonged use though less common than with unfractionated heparin
Thrombocytopenia resulting in abnormally low blood platelet counts
Rare instances of alopecia
Fever and chills reported in some cases
Hypersensitivity reactions related to benzyl alcohol preservative in multi-dose vials
Localized hematomas or prolonged bleeding at injection sites

Precautions

Use with caution in patients with active or recent bleeding disorders
Monitor platelet counts regularly to detect potential heparin-induced thrombocytopenia
Adjust doses in patients with renal impairment to prevent drug accumulation
Avoid intramuscular injections to reduce risk of hematoma formation
Exercise caution in patients with uncontrolled hypertension or history of hemorrhagic stroke
Close monitoring required in elderly patients due to increased bleeding risk
Assess for history of hypersensitivity to heparin, enoxaparin, or pork products
Do not use in patients with known sensitivity to benzyl alcohol unless preservative-free formulation used
Avoid concurrent use with other anticoagulants unless specifically directed
Consider risk of spinal or epidural hematoma with neuraxial anesthesia or spinal puncture
Evaluate benefit-risk ratio in pregnant patients, especially those with mechanical heart valves
Monitor for signs of bleeding in patients with gastrointestinal ulcers or recent surgery
Inform patients about proper injection sites and rotation to prevent local complications
Ensure proper storage and discard after 28 days once vial is opened
Educate patients to report any unusual bruising, bleeding, or neurological symptoms promptly

Warnings

Contraindicated in patients with active major bleeding
Do not use in patients with history of heparin-induced thrombocytopenia with positive antibodies
Risk of spinal or epidural hematoma leading to paralysis when used with spinal anesthesia or epidural catheter
Risk increased with concurrent use of blood thinners, NSAIDs, or history of spinal surgery or trauma
Avoid use in patients with uncontrolled bleeding or bleeding disorders
Discontinue prior to spinal or epidural procedures as per clinical guidelines
Monitor closely for signs of neurological impairment indicating possible spinal hematoma
Not recommended for patients with significant thrombocytopenia unrelated to HIT
Carry risk of severe bleeding; emergency medical attention required for symptoms such as black stools or severe headache
Pregnant patients with mechanical heart valves at increased risk; use only if benefit outweighs risk
Permanent paralysis may occur if spinal hematoma is not promptly treated
Use caution in patients with severe renal impairment due to accumulation and increased bleeding risk
Report any signs of allergic reactions immediately
Use preservative-free formulations during pregnancy to avoid benzyl alcohol exposure
Do not share syringes or needles; single-use only

Contraindication

Active, uncontrolled major bleeding
History of heparin-induced thrombocytopenia with positive antibodies within past 100 days
Hypersensitivity to enoxaparin, heparin, benzyl alcohol, or pork products
Known bleeding disorders that predispose to bleeding
Severe thrombocytopenia
Patients currently undergoing spinal puncture, spinal anesthesia, or having recently undergone such procedures without proper risk evaluation
Increased risk of hemorrhagic complications post brain, spine, or eye surgery
Concomitant use of other anticoagulants without strict clinical indication and monitoring
Known hypersensitivity or allergy to any component of the formulation
Patients with active gastric or intestinal ulcers with bleeding
Severe uncontrolled hypertension with risk of bleeding
Patients with bacterial endocarditis due to risk of bleeding complications
Pregnant patients with mechanical prosthetic heart valves unless carefully managed by specialists
In patients with severe renal impairment, unless dose has been adjusted appropriately

Drug Interactions

Concurrent use with aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) increases bleeding risk
Increased bleeding potential when used with warfarin or other vitamin K antagonists
Interactions with other anticoagulants such as apixaban, rivaroxaban, dabigatran, desirudin, or fondaparinux leading to enhanced anticoagulant effect
Use with platelet aggregation inhibitors like clopidogrel, ticlopidine, cilostazol may increase bleeding risk
Combination with fibrinolytic drugs such as alteplase, reteplase, tenecteplase, or urokinase increases hemorrhage risk
Concurrent therapy with glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban) may potentiate anticoagulation
May interact with anagrelide, dipyridamole, and other antiplatelet agents by elevating bleeding chance
Careful consideration when used with drugs affecting hemostasis to avoid additive bleeding complications
Benzyl alcohol preservative in multi-dose vials may interact with other benzyl alcohol containing medications leading to toxicity, especially in neonates
Interaction with drugs that impair renal function may alter enoxaparin clearance
Herbal supplements like ginkgo biloba, garlic, or ginseng may have additive anticoagulant effects
Drugs that induce or inhibit hepatic metabolism enzymes have minimal impact but should be monitored due to complex hemostatic balance
Concurrent use of systemic corticosteroids may increase risk of gastrointestinal bleeding
Use with care in patients taking selective serotonin reuptake inhibitors (SSRIs) due to increased bleeding risk
Other drugs that affect platelet function or coagulation warrant close monitoring

Preparations Of The Drug

Prefilled single-use syringes with fixed dosages ranging from 30 mg to 150 mg per mL
Multi-dose vials containing 300 mg/3 mL or 400 mg/4 mL with benzyl alcohol preservative
Preservative-free formulations available for use in pregnant women and patients sensitive to benzyl alcohol
Storage at controlled room temperature, protected from moisture and heat
Packaging typically includes syringes with attached needles or separate needles for subcutaneous administration
Single-dose administration recommended; syringes and needles are discarded immediately after use
Different syringe sizes to accommodate weight-based dosing for tailored patient therapy
Supplied with detailed administration instructions including injection site rotation guidance
Formulations designed for subcutaneous injection with rapid and predictable absorption
Injection devices designed for patient self-administration or healthcare provider use
Sterile, non-pyrogenic, and preservative variations to accommodate different patient populations
Availability of generic enoxaparin versions bioequivalent to Lovenox
Labeling includes warnings about potential risks such as spinal hematoma and bleeding
Educational materials often distributed with medication to improve patient safety and compliance
Disposal instructions provided for sharps containers to ensure environmental safety